Literature DB >> 8697160

Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.

N C Davidson1, W J Coutie, D J Webb, A D Struthers.   

Abstract

OBJECTIVE: To assess the differential effects of low dose (5 mg) and high dose (20 mg) lisinopril treatment on cardiovascular hormones, renal function, and blood pressure over 24 hours in patients with heart failure.
DESIGN: Double-blind crossover study.
SETTING: Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee. PATIENTS: 19 patients with chronic heart failure and left ventricular ejection fraction < or = 45%.
RESULTS: Plasma concentrations of aldosterone and endothelin were lower on the 20 mg dose (plasma aldosterone mean at peak drug effect: 90.7 v 152.0 pg/ml, P < 0.001; mean at trough effect: 124.7 v 174.4 pg/ml, P < 0.01; plasma endothelin at trough effect 4.70 v 6.04 pmol/l, P = 0.03). Creatinine clearance was lower on 20 mg lisinopril (68.7 v 82.1 ml/min, P < 0.05). The area under the curve for diastolic blood pressure over 24 hours was significantly lower on 20 mg (mean difference 3.0 mm Hg, P = 0.04); for systolic blood pressure there was a similar trend (mean difference 5.7 mmHg, P = 0.05). Plasma concentrations of atrial natriuretic peptide (ANP) and B-type natriuretic peptide were similar for both doses; urinary excretion of ANP was lower on 20 mg (12.2 v 13.6 pmol, P < 0.05).
CONCLUSIONS: These results indicate that within the usual therapeutic range, high doses of lisinopril cause greater suppression of selected cardiovascular hormones than low doses in heart failure, but are associated with lower creatinine clearance in some patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8697160      PMCID: PMC484380     

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  18 in total

1.  THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS.

Authors:  J E GRIZZLE
Journal:  Biometrics       Date:  1965-06       Impact factor: 2.571

2.  A continuous spectrophotometric assay for angiotensin converting enzyme.

Authors:  B Holmquist; P Bünning; J F Riordan
Journal:  Anal Biochem       Date:  1979-06       Impact factor: 3.365

3.  Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm.

Authors:  N Benjamin; J R Cockcroft; J G Collier; C T Dollery; J M Ritter; D J Webb
Journal:  J Physiol       Date:  1989-05       Impact factor: 5.182

4.  NHLBI funding policies. Enhancing stability, predictability, and cost control.

Authors:  C Lenfant
Journal:  Circulation       Date:  1994-07       Impact factor: 29.690

5.  Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide.

Authors:  C Boulanger; T F Lüscher
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

6.  Effect of angiotensin converting enzyme inhibition on plasma endothelin in congestive heart failure.

Authors:  J Townend; J Doran; S Jones; M Davies
Journal:  Int J Cardiol       Date:  1994-03-01       Impact factor: 4.164

7.  N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction.

Authors:  C Hall; J L Rouleau; L Moyè; J de Champlain; D Bichet; M Klein; B Sussex; M Packer; J Rouleau; M O Arnold
Journal:  Circulation       Date:  1994-05       Impact factor: 29.690

8.  Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension.

Authors:  R Pacher; J Bergler-Klein; S Globits; H Teufelsbauer; M Schuller; A Krauter; E Ogris; S Rödler; M Wutte; E Hartter
Journal:  Am J Cardiol       Date:  1993-06-01       Impact factor: 2.778

9.  Plasma endothelin in chronic heart failure.

Authors:  J J McMurray; S G Ray; I Abdullah; H J Dargie; J J Morton
Journal:  Circulation       Date:  1992-04       Impact factor: 29.690

10.  PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1).

Authors:  B Rigat; C Hubert; P Corvol; F Soubrier
Journal:  Nucleic Acids Res       Date:  1992-03-25       Impact factor: 16.971

View more
  5 in total

Review 1.  Lisinopril: a review of its use in congestive heart failure.

Authors:  K Simpson; B Jarvis
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

2.  A survey of the dose of ACE inhibitors prescribed by general physicians for patients with heart failure.

Authors:  R McMullan; B Silke
Journal:  Postgrad Med J       Date:  2001-12       Impact factor: 2.401

3.  Endothelin in heart failure: a promising therapeutic target?

Authors:  M P Love; J J McMurray
Journal:  Heart       Date:  1997-02       Impact factor: 5.994

4.  Non-adherence with ACE inhibitor treatment is common in heart failure and can be detected by routine serum ACE activity assays.

Authors:  A D Struthers; G Anderson; R J MacFadyen; C Fraser; T M MacDonald
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

5.  How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

Authors:  R J MacFadyen; A F Lee; J J Morton; S D Pringle; A D Struthers
Journal:  Heart       Date:  1999-07       Impact factor: 5.994

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.